146667-87-0 Usage
General Description
3-Vinyl-piperidine-1-carboxylic acid tert-butyl ester is a chemical compound that has several key characteristics. It contains a vinyl group, a piperidine ring, and a carboxylic acid functional group. The tert-butyl ester moiety adds steric hindrance to the molecule, influencing its reactivity and stability. The compound has potential applications in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. Its unique structure and functional groups make it a versatile building block for the creation of complex molecules. However, as with any chemical compound, it is important to handle and use 3-Vinyl-piperidine-1-carboxylic acid tert-butyl ester with caution and in accordance with safety guidelines.
Check Digit Verification of cas no
The CAS Registry Mumber 146667-87-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,6,6,6 and 7 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 146667-87:
(8*1)+(7*4)+(6*6)+(5*6)+(4*6)+(3*7)+(2*8)+(1*7)=170
170 % 10 = 0
So 146667-87-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H21NO2/c1-5-10-7-6-8-13(9-10)11(14)15-12(2,3)4/h5,10H,1,6-9H2,2-4H3
146667-87-0Relevant articles and documents
PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS
-
Paragraph 0648; 0649; 0650, (2014/02/15)
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, and autoimmune conditions.
Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
-
Page/Page column 62, (2009/08/14)
Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
